Urology Times staff

At standard stimulation parameters, the Axonics F15 system is expected to function for 15+ years; at lower energy settings, this extends to 20+ years.

“We should be really trying to raise the profile of bladder symptoms [and] functional urology issues, and educating colleagues on how to inquire about and capture that information as effectively as possible,” says Jai Seth, MD, BSc, MSc, FRCS.

Abstracts highlight topics such as sacral neuromodulation and percutaneous tibial nerve stimulation.

In this installment of the Urology Times' 50th Anniversary Innovation Celebration, Kara L. Watts, MD, discusses the emergence and increasing uptake of active surveillance as a management strategy for men with prostate cancer.

“I think results from this study introduce a new standard of care for patients with metastatic hormone-sensitive prostate cancer, where we clearly need to do better than what we're doing today, since the sequence of therapy seems to be less effective than hitting them hard upfront,” says Fred Saad, MD, FRCS.

The filing is based on findings from the placebo-controlled phase 3 ARASENS trial.

"Active surveillance is an innovation because it's truly a departure from the idea that all prostate cancers or cancer, in general, needs to be treated," says Kara L. Watts, MD.

The device is indicated for overactive bladder, chronic fecal incontinence, and non-obstructive urinary retention.

“I think initiating a conversation with a patient needs to start earlier, possibly even earlier than just at the point of giving them a diagnosis,” says Netty Kinsella, RN, MSc, PhD.

“The proportion of clinics that employ an onsite urologist, where the urologist is integrated into the flow of that clinic, is relatively small,” says Akanksha Mehta, MD, MS.

“The majority of patients were able to stay on the dose of the apalutamide,” says Mario E. Lacouture, MD.

Janet Kukreja, MD, recaps 5 presentations from the 2022 Genitourinary Cancers Symposium.

“Whether a patient goes on to have radiation therapy, radical surgery, or focal therapy, or a whole host of other types of surgery or prostate cancer treatment that may follow, [that] can largely dictate where they may end up on the spectrum of having a bladder problem, a bladder outlet problem, or a urethral problem,” says Jai Seth, MD, BSc, MSc, FRCS.

“I think we're at a point where we have this luxury of many options, which is great, but we still need to continue to be really thoughtful in how we choose those options,” says Benjamin Lowentritt, MD, FACS.

“I think the audience would be encouraged to know that in the future, it seems like immunotherapy would become the standard of care,” says Shilpa Gupta, MD.

“I think that the audience should know that there is a movement going on,” says Geo Espinosa, ND.

“I think that we keep getting better and better tools…[and] I think understanding how to utilize these tools will be a challenge in the future,” says David M. Schuster, MD, FACR.

“The idea is to develop strategies that reduce the likelihood of needing a biopsy or improving the sensitivity of the biopsy to find a high-grade cancer, one that's treatable,” says Eric A. Klein, MD.

“The management of hereditary upper tract cancer and Lynch syndrome [is] a multidisciplinary approach,” says Hong Truong, MD.

“We need to look at tumors a little bit differently. Not so much put them in the same categories, but really look at them based on whether the mutation is as identified in that specific marker,” says Philippe E. Spiess, MD, MS, FRCSC, FACS.

“I think that [these findings] definitely [warrant] standard of care radiation and hormone therapy for these patients or other forms of radical therapy,” says Daniel E. Spratt, MD.

“Patients are interested in exercise, they're really keen, they want to know what they can do to help themselves,” says Kerry S. Courneya, PhD.

“It's just working together as a team to recognize that this needs to be an ongoing active conversation about achieving autonomy in the operating room,” says Kate H. Kraft, MD.

“This study really showed that we went now beyond 2 years for radiographic progression-free survival, which is the longest we've ever seen in the first-line setting,” says Fred Saad, MD, FRCS.

At the 2022 ASCO Genitourinary Cancers Symposium, Neal D. Shore, MD, FACS, presented findings of the prospective study, "Hereditary cancer risk assessment in the community urology practice setting."

“The complete response rates were 49%, which is quite impressive compared to historical controls,” says Shilpa Gupta, MD.

In this installment of the Urology Times' 50th Anniversary Innovation Celebration, Arthur L. Burnett, MD, MBA, FACS, discusses how sildenafil citrate (Viagra) has been an integral part of erectile dysfunction management for decades.

“We're all students on this journey, and things change and evolve,” says Polina X. Reyblat, MD.

“We found in this study that the exercise group had lower prostate cancer-specific anxiety compared to the group that didn't exercise,” says Kerry Courneya, PhD.

"Viagra has revolutionized the field of sexual medicine and impacted how we go about therapies," says Arthur L. Burnett, MD, MBA, FACS.